Respiratory specialist Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said its chief medical officer, Kenneth Newman, is quitting the company at the end of the month to “pursue other opportunities”.
The search is already underway for his replacement.
Chief executive Jan-Anders Karlsson thanked Newman for his “outstanding service” over the past three years.
This included the acceleration into phase IIb clinical trials of Verona’s chronic obstructive pulmonary disease drug candidate.
In total, Newman oversaw seven clinical trials and played an instrumental role in establishing the drug developer’s US presence.